Research Analysts Issue Forecasts for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a research note issued to investors on Monday, November 10th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($2.69) for the year, down from their prior estimate of ($2.33). The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share. Cantor Fitzgerald also issued estimates for Cartesian Therapeutics’ FY2026 earnings at ($3.51) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last released its earnings results on Thursday, November 6th. The company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.57). The firm had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.18 million.

Other research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Cartesian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Cartesian Therapeutics in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Cartesian Therapeutics Stock Up 3.8%

Cartesian Therapeutics stock opened at $7.58 on Wednesday. The stock has a market cap of $197.11 million, a price-to-earnings ratio of -4.86 and a beta of 0.44. Cartesian Therapeutics has a 12-month low of $5.98 and a 12-month high of $26.50. The business’s 50-day simple moving average is $9.27 and its 200 day simple moving average is $10.44.

Institutional Investors Weigh In On Cartesian Therapeutics

Hedge funds have recently bought and sold shares of the company. Virtus Investment Advisers LLC boosted its position in shares of Cartesian Therapeutics by 12.5% during the second quarter. Virtus Investment Advisers LLC now owns 9,183 shares of the company’s stock worth $95,000 after purchasing an additional 1,023 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Cartesian Therapeutics by 7.9% during the 1st quarter. Bank of New York Mellon Corp now owns 20,937 shares of the company’s stock worth $276,000 after buying an additional 1,530 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Cartesian Therapeutics by 9.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 29,303 shares of the company’s stock worth $386,000 after acquiring an additional 2,500 shares in the last quarter. AlphaQuest LLC lifted its holdings in Cartesian Therapeutics by 64.6% during the third quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock worth $71,000 after acquiring an additional 2,717 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Cartesian Therapeutics by 27.5% in the first quarter. Rhumbline Advisers now owns 13,006 shares of the company’s stock valued at $171,000 after acquiring an additional 2,805 shares during the period. 86.95% of the stock is currently owned by institutional investors and hedge funds.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.